The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Open accessAbstract
Purpose: The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown. S0809 was designed to estimate 2-year survival (overall and after R0 or R1 resection), pattern of relapse, and toxicity in patients treated with this adjuvant regimen. Patients and Methods: Eligibility criteria included diagnosis of EHCC or GBCA after radical resection, stage pT2-4 or N+ or positive resection margins, M0, and performance status 0 to 1. Patients received four cycles of gemcitabine (1,000 mg/m 2 intravenously on days 1 and 8) and capecitabine (1,500 mg/m 2 per day on days 1 to 14) every 21 days followed by concurrent capecitabine (1,330 mg/m 2 per day) and radiotherapy (45 Gy to regional lymphatics; 54 to 59.4 Gy to tumor bed). With 80 evaluable patients, results would be promising if 2-year survival 95% CI were > 45% and R0 and R1 survival estimates were ≥ 65% and 45%, respectively. Results: A total of 79 eligible patients (R0, n = 54; R1, n = 25; EHCC, 68%; GBCA, 32%) were treated (86% completed). For all patients, 2-year survival was 65% (95% CI, 53% to 74%); it was 67% and 60% in R0 and R1 patients, respectively. Median overall survival was 35 months (R0, 34 months; R1, 35 months). Local, distant, and combined relapse occurred in 14, 24, and nine patients. Grade 3 and 4 adverse effects were observed in 52% and 11% of patients, respectively. The most common grade 3 to 4 adverse effects were neutropenia (44%), hand-foot syndrome (11%), diarrhea (8%), lymphopenia (8%), and leukopenia (6%). There was one death resulting from GI hemorrhage. Conclusion: This combination was well tolerated, has promising efficacy, and provides clinicians with a well-supported regimen. Our trial establishes the feasibility of conducting national adjuvant trials in EHCC and GBCA and provides baseline data for planning future phase III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Horgan, A. M., Amir, E., Walter, T., & Knox, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5381 · Cited by 716
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
Khan, S. A., Davidson, B. R., Goldin, R., Pereira, S. P., Rosenberg, W. M. C., Taylor-Robinson, S. D., Thillainayagam, A. V., Thomas, H. C., Thursz, M. R., & Wasan, H. (2002) · Gut · doi:10.1136/gut.51.suppl_6.vi1 · Cited by 648
Burke, E. C., Jarnagin, W. R., Hochwald, S. N., Pisters, P. W. T., Fong, Y., & Blumgart, L. H. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00011 · Cited by 468
Jarnagin, W. R., Ruo, L., Little, S. A., Klimstra, D., D'Angelica, M., DeMatteo, R. P., Wagman, R., Blumgart, L. H., & Fong, Y. (2003) · Cancer · doi:10.1002/cncr.11699 · Cited by 454
André, T., Tournigand, C., Rosmorduc, O., Provent, S., Maindrault-Goebel, F., Avenin, D., Selle, F., Paye, F., Hannoun, L., Houry, S., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh351 · Cited by 380
Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial
Knox, J. J., Hedley, D. W., Oza, A. M., Feld, R., Siu, L. L., Chen, E. X., Nematollahi, M., Pond, G. R., Zhang, J., & Moore, M. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.51.008 · Cited by 305
Perihilar Cholangiocarcinoma Postoperative Radiotherapy Does Not Improve Survival
Pitt, H. A., Nakeeb, A., Abrams, R. A., Coleman, J., Piantadosi, S., Yeo, C. J., Lillemoe, K. D., & Cameron, J. L. (1995) · Annals of Surgery · doi:10.1097/00000658-199506000-00017 · Cited by 299
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
Shroff, R. T., Kennedy, E. B., Bachini, M., Bekaii-Saab, T., Crane, C., Edeline, J., El-Khoueiry, A., Feng, M., Katz, M. H. G., Primrose, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02178 · Cited by 445
Self-citationCholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Khosla, D., Misra, S., Chu, P. L., Guan, P., Nada, R., Gupta, R., Kaewnarin, K., Ko, T. K., Heng, H. L., Srinivasalu, V. K., et al. (2024) · Cancers · doi:10.3390/cancers16040801 · Cited by 44
Metadata
- Authors
- Ben-Josef, E., Guthrie, K. A., El-Khoueiry, A. B., Corless, C. L., Zalupski, M. M., Lowy, A. M., Thomas, C. R., Alberts, S. R., Dawson, L. A., Micetich, K. C., Thomas, M. B., Siegel, A. B., & Blanke, C. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-08-20
- Volume
- 33
- Issue
- 24
- Pages
- 2617-2622
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2124474327
- Cited by
- 420
- References
- 20
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2014.60.2219
- The paper
- Ben-Josef, E., Guthrie, K. A., El-Khoueiry, A. B., Corless, C. L., Zalupski, M. M., Lowy, A. M., Thomas, C. R., Alberts, S. R., Dawson, L. A., Micetich, K. C., Thomas, M. B., Siegel, A. B., & Blanke, C. D. (2015). SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.60.2219
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
